"In twelve months this should see a share price at approximately $50. A takeover at that time, with risks reduced and future potential identifiable then a healthy premium takeover towards $150 is not unreasonable." Given that Neuren, post FDA approval, is now trading at a price around the same as after successful phase 2 results, why would a buyer pay a 300% premium?
NEU Price at posting:
$18.65 Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)